It is overexpressed in breast, thyroid, hepatocellular, prostate, pancreatic, gastric, lung and ovarian cancers [34]–[37], and small molecule inhibitors of Sp1 have been tested in pre-clinical models with successful reduction in tumor burden [38], [39]. Here, SP1 is linked to ovarian cancer.